Details

Autor(en) / Beteiligte

• Marso, Steven P
• Bain, Stephen C
• Consoli, Agostino
• Eliaschewitz, Freddy G
• Jódar, Esteban
• Leiter, Lawrence A
• Lingvay, Ildiko
• Rosenstock, Julio
• Seufert, Jochen
• Warren, Mark L
• Woo, Vincent
• Hansen, Oluf
• Holst, Anders G
• Pettersson, Jonas
• Vilsbøll, Tina

Titel

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Ist Teil von

• The New England journal of medicine, 2016-11, Vol.375 (19), p.1834-1844

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Patients with type 2 diabetes at high cardiovascular risk received either once-weekly semaglutide, a glucagon-like peptide 1 analogue, or placebo. The rate of a first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke was significantly lower with semaglutide. Cardiovascular disease is the leading cause of death and complications in patients with type 2 diabetes. 1 Recently, trials evaluating a sodium–glucose cotransporter 2 inhibitor (empagliflozin) and a glucagon-like peptide 1 (GLP-1) analogue (liraglutide) have shown improved cardiovascular outcomes in patients with type 2 diabetes who were at high risk for cardiovascular events. 2 , 3 Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4 is currently in development but not yet approved for the treatment of type 2 diabetes. Regulatory guidance specifies the need to establish the cardiovascular safety of new therapies for type . . .